SRRK

Scholar Rock Holding Corp

42.49

Oct 27 • 3:59 PM ET +0.78 (1.87%)

43.86

Aftermarket • 7:59 PM ET +1.37 (3.22%)

Healthcare Biotechnology USA Mid NASD

Peers: BHVN PTCT DYN BIIB SRPT EWTX REGN CYTK NVS KROS

| Held by: VTI IWM XBI VB VXF IWO VBK IBB VTWO SCHA

Index	RUT
Market Cap	5.17B
Enterprise Value	4.89B
Income	-408.59M
Sales	0.00M
Book/sh	2.09
Cash/sh	4.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	289
IPO	May 24, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	20.36
P/C	10.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.02
Current Ratio	7.02
Debt/Eq	0.80
LT Debt/Eq	0.78
Option/Short	Yes / Yes

EPS (ttm)	-3.45
EPS next Y	-2.61
EPS next Q	-0.85
EPS this Y	-1.37%
EPS next Y	21.73%
EPS next 5Y	27.07%
EPS past 3/5Y	-13.45% -3.21%
Sales past 3/5Y	- -
EPS Y/Y TTM	-14.40%
Sales Y/Y TTM	-
EPS Q/Q	13.82%
Sales Q/Q	-
Earnings	Nov 10 BMO
EPS/Sales Surpr.	0.06% -

Insider Own	17.26%
Insider Trans	1.31%
Inst Own	101.15%
Inst Trans	4.41%
ROA	-94.63%
ROE	-167.77%
ROIC	-90.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.14%
SMA50	-13.59%
SMA200	-11.87%
Trades

Shs Outstand	121.60M
Shs Float	100.76M
Short Float	22.01%
Short Ratio	13.30
Short Interest	22.18M
52W High	61.76 -31.20%
52W Low	27.07 56.96%
Volatility	3.67% 4.44%
ATR (14)	1.94
RSI (14)	43.20
Beta	0.78
Rel Volume	0.70
Avg Volume	1.67M
Volume	1,160,672

Perf Week	2.73%
Perf Month	-13.52%
Perf Quarter	-13.39%
Perf Half Y	-9.07%
Perf YTD	-3.54%
Perf Year	39.31%
Perf 3Y	310.93%
Perf 5Y	63.42%
Perf 10Y	-
Recom	1.11
Target Price	69.12
Prev Close	41.71
Price	42.49
Change %	1.87%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-26	Downgrade	Barclays	Overweight → Equal Weight	$58
Apr-21-26	Initiated	Canaccord Genuity	Buy	$62
Jan-09-26	Initiated	Citigroup	Buy	$55
Nov-18-25	Initiated	Wolfe Research	Outperform	$42
Oct-09-25	Initiated	BofA Securities	Buy	$53
Sep-17-25	Initiated	Barclays	Overweight	$45
Sep-15-25	Initiated	Leerink Partners	Outperform	$51
Aug-21-25	Resumed	Jefferies	Buy	$50
Jul-30-25	Resumed	Raymond James	Strong Buy	$53
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56

Show Previous Ratings

Oct-20-26 08:00AM	Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 (Business Wire)
Oct-16-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-08-26 08:00AM	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire)
Oct-02-26 09:00AM	3 drug targets pharma is betting on next (Pharma Voice)
Sep-28-26 06:44AM	FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals (Stocktwits)
12:00PM	Loading…
Sep-21-26 12:00PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-18-26 06:43AM	This week in charts: GSKs China deals, the $300M IPO club and selling the news (BioPharma Dive)
Sep-14-26 04:30PM	SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug But Wall Street Hikes Price Targets (Stocktwits) -6.42%
08:08AM	Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy (InvestorsHub)
07:41AM	Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump (Investing.com)
05:00AM	Scholar Rock SMA drug approved by FDA (BioPharma Dive)
Sep-11-26 07:31PM	Second Times The Charm: FDA Clears Scholar Rocks SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours (Stocktwits)
06:25PM	Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-02-26 08:00AM	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial (Business Wire)
Aug-27-26 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire)
05:50PM	Loading…
Aug-21-26 05:50PM	SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing (Stocktwits)
09:06AM	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan (Business Wire)
Aug-14-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-26 04:20PM	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date (Business Wire)
Aug-06-26 03:02PM	Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ... (GuruFocus.com) +9.96%
07:00AM	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights (Business Wire)
Jul-29-26 08:00AM	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Jul-20-26 08:00AM	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) (Business Wire)
04:54AM	Bristol Myers to build powerful AI factory; Samsung Biologics bids for peptide maker (BioPharma Dive)
Jul-17-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-26 08:00AM	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jun-22-26 08:00AM	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD (Business Wire)
Jun-12-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-26 09:30AM	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire) +7.02%
May-20-26 08:00AM	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference (Business Wire)
04:15PM	Loading…
May-15-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-26 07:00AM	Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights (Business Wire)
Apr-29-26 08:00AM	Scholar Rock to Present at the BofA Securities 2026 Health Care Conference (Business Wire)
Apr-17-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-26 08:00AM	Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Mar-31-26 07:00AM	Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire) +14.11%
Mar-13-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-26 01:30PM	Scholar Rock Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Feb-18-26 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-26 08:00AM	Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire)
Jan-16-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-26 07:00AM	Scholar Rock Highlights 2026 Strategic Priorities (Business Wire)
Jan-05-26 08:00AM	Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-25 10:57AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-25 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire) +9.14%
Nov-16-25 11:16AM	Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses (Insider Monkey)
Nov-15-25 07:07AM	Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress (Insider Monkey)
Nov-14-25 02:02PM	Scholar Rock Holding Corp (SRRK) Q3 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com) +24.41%
07:00AM	Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:15AM	3 Beaten-Down Stocks With Rebound Potential This Earnings Season (MarketBeat)
Nov-04-25 08:00AM	Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-23-25 08:00AM	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 (Business Wire)
Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Oct 26 '26	Buy	41.59	146,970	6,112,482	6,380,517	Oct 27 07:47 PM
AKKARAJU SRINIVAS	Director	Oct 23 '26	Buy	41.32	142,500	5,887,440	6,331,529	Oct 27 07:47 PM
Katie Peng	Director	Oct 01 '26	Proposed Sale	48.32	1,006	48,610		Oct 01 04:19 PM
FLIER JEFFREY S.	Director	Jul 01 '26	Sale	53.88	3,053	164,490	27,856	Jul 06 04:30 PM
Gilman Michael	Director	Jul 01 '26	Sale	53.87	2,544	137,058	59,511	Jul 06 04:30 PM
Burow Kristina	Director	Jul 01 '26	Sale	53.74	3,053	164,064	114,657	Jul 06 04:30 PM
Reed Joshua	Director	Jul 01 '26	Sale	53.74	3,053	164,067	19,518	Jul 06 04:30 PM
Peng Katie	Director	Jul 01 '26	Sale	53.88	5,446	293,405	34,301	Jul 06 04:30 PM
Mohammed Qatanani	Officer	Jul 06 '26	Proposed Sale	54.68	11,704	639,975		Jul 06 04:22 PM
Joshua Reed	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:58 PM
Jeffrey S. Flier	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:55 PM
Kristina Burow	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:52 PM
Michael Gilman	Director	Jul 01 '26	Proposed Sale	54.79	2,544	139,385		Jul 01 04:46 PM
Katie Peng	Director	Jul 01 '26	Proposed Sale	54.79	5,446	298,386		Jul 01 04:44 PM
Burow Kristina	Director	Apr 23 '26	Option Exercise	9.14	89,800	820,324	110,871	Apr 24 04:05 PM
Woods Keith	Chief Operating Officer	Apr 16 '26	Sale	49.57	10,220	506,651	620,055	Apr 20 06:12 PM
Vaishnaw Akshay	President of R&D	Apr 16 '26	Sale	49.57	12,246	607,089	630,542	Apr 20 06:10 PM
Sinha Vikas	Chief Financial Officer	Apr 16 '26	Sale	49.57	10,410	516,071	619,856	Apr 20 06:09 PM
Hallal David	Chief Executive Officer	Apr 16 '26	Sale	49.57	30,615	1,517,723	1,639,034	Apr 20 06:08 PM
Mohammed Qatanani	Officer	Apr 06 '26	Proposed Sale	50.01	23,408	1,170,634		Apr 06 04:11 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 23 '26	Sale	47.07	8,484	399,351	98,445	Feb 25 05:55 PM
Mohammed Qatanani	Officer	Feb 23 '26	Proposed Sale	48.32	8,484	409,947		Feb 23 04:05 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Feb 17 '26	Sale	46.53	4,157	193,418	126,012	Feb 19 04:30 PM
Ho Junlin	GENERAL COUNSEL	Feb 17 '26	Sale	46.53	9,580	445,740	241,545	Feb 19 04:30 PM
Parlavecchio Caryn	CHRO	Feb 17 '26	Sale	46.53	9,035	420,382	169,087	Feb 19 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 17 '26	Sale	46.53	7,989	371,714	106,929	Feb 19 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 22 '26	Sale	46.71	14,898	695,938	85,660	Jan 23 04:30 PM
Mohammed Qatanani	Officer	Jan 22 '26	Proposed Sale	46.05	14,898	686,053		Jan 22 04:14 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '26	Sale	44.48	8,406	373,880	100,558	Jan 21 07:52 PM
Parlavecchio Caryn	CHRO	Jan 16 '26	Sale	44.48	6,600	293,553	148,864	Jan 21 07:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '26	Sale	44.48	5,798	257,882	95,687	Jan 21 07:50 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '26	Sale	44.48	8,016	356,533	214,553	Jan 21 07:50 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Option Exercise	18.53	13,112	242,961	122,076	Jan 16 06:37 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Sale	45.20	13,112	592,611	108,964	Jan 16 06:37 PM
Sinha Vikas	Chief Financial Officer	Jan 13 '26	Sale	42.70	16,755	715,438	583,245	Jan 15 07:58 PM
Woods Keith	Chief Operating Officer	Jan 13 '26	Sale	42.70	16,746	715,054	583,254	Jan 15 07:57 PM
Vaishnaw Akshay	President of R&D	Jan 13 '26	Sale	42.70	20,438	872,703	595,767	Jan 15 07:56 PM
Hallal David	Chief Executive Officer	Jan 13 '26	Sale	42.70	57,450	2,453,115	1,541,645	Jan 15 07:54 PM
Peng Katie	Director	Dec 16 '25	Sale	44.09	1,006	44,352	32,908	Dec 18 04:30 PM
Katie Peng	Director	Dec 16 '25	Proposed Sale	45.24	1,006	45,511		Dec 16 06:02 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Option Exercise	21.21	136,462	2,894,077	245,426	Dec 05 04:53 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Sale	45.21	136,462	6,169,788	108,964	Dec 05 04:53 PM
Mohammed Qatanani	Officer	Dec 04 '25	Proposed Sale	43.01	149,574	6,433,178		Dec 04 04:19 PM

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

CEO & Chairman of the BoardMr. David L. Hallal

CPAMr. Vikas Sinha C.A.

Chief Operating OfficerMr. Robert Keith Woods

Ph.D.Dr. Akshay Krishnadas Vaishnaw M.D.

Interim Principal Financial & Accounting OfficerMs. Erin Moore CPA

Open in Screener

ALMS

Alumis Inc

6.64

Oct 27 • 3:59 PM ET +0.13 (2.00%)

6.50

Aftermarket • 7:32 PM ET -0.14 (-2.11%)

Healthcare Biotechnology USA Small NASD

Peers: PTGX ORKA MLTX VRDN TAK BMY ARQT ACRS KYMR SYRE

| Held by: VTI IWM VXF XPH IWO IBB VTWO SCHA IHE VHT

Index	RUT
Market Cap	886.40M
Enterprise Value	420.54M
Income	-438.96M
Sales	7.40M
Book/sh	3.52
Cash/sh	3.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	224
IPO	Jun 28, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	119.78
P/B	1.89
P/C	1.76
P/FCF	-
EV/EBITDA	-
EV/Sales	56.83
Quick Ratio	6.74
Current Ratio	6.74
Debt/Eq	0.08
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-3.81
EPS next Y	-2.82
EPS next Q	-0.75
EPS this Y	-14.16%
EPS next Y	13.66%
EPS next 5Y	10.01%
EPS past 3/5Y	-9.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	15.36%
Sales Y/Y TTM	-63.11%
EPS Q/Q	-243.88%
Sales Q/Q	-37.66%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-44.85% -54.49%

Insider Own	28.54%
Insider Trans	2.34%
Inst Own	67.14%
Inst Trans	3.04%
ROA	-74.94%
ROE	-93.65%
ROIC	-90.74%
Gross Margin	52.31%
Oper. Margin	-5479.55%
Profit Margin	-5933.45%
SMA20	-1.51%
SMA50	-38.96%
SMA200	-69.33%
Trades

Shs Outstand	124.45M
Shs Float	95.39M
Short Float	11.62%
Short Ratio	4.37
Short Interest	11.08M
52W High	31.35 -78.82%
52W Low	4.39 51.43%
Volatility	5.44% 5.87%
ATR (14)	0.53
RSI (14)	33.67
Beta	-0.31
Rel Volume	1.29
Avg Volume	2.54M
Volume	3,261,323

Perf Week	-0.90%
Perf Month	-7.26%
Perf Quarter	-74.83%
Perf Half Y	-72.36%
Perf YTD	-31.97%
Perf Year	38.05%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.30
Target Price	31.12
Prev Close	6.51
Price	6.64
Change %	2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-26	Downgrade	Guggenheim	Buy → Neutral
Sep-02-26	Upgrade	H.C. Wainwright	Neutral → Buy	$15
May-15-26	Downgrade	H.C. Wainwright	Buy → Neutral	$25
Mar-11-26	Initiated	Raymond James	Strong Buy	$46
Feb-25-26	Initiated	Stifel	Buy	$44
Jan-21-26	Initiated	Chardan Capital Markets	Buy	$37
Jul-25-25	Initiated	Wells Fargo	Overweight	$17
Jun-10-25	Resumed	Guggenheim	Buy	$18
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Oct-09-26 01:11PM	Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact (Clinical Trials Arena)
04:00AM	Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures (GlobeNewswire)
Sep-04-26 08:00AM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-01-26 07:55PM	ALMS Stock Clocks Worst Day After 57% Drop What Drove The Selloff? (Stocktwits) -56.58% +9.29%
01:23PM	A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It (Barrons.com)
10:03AM	Loading…
10:03AM	Alumis Phase 2b lupus trial misses primary and secondary endpoints (InvestorsHub)
07:30AM	Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
07:28AM	Alumis TYK2 drug fails in key lupus study (BioPharma Dive)
Aug-13-26 04:01PM	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Aug-10-26 04:05PM	Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies (GlobeNewswire) -7.85%
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive) -7.15%
May-14-26 04:05PM	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-28-26 01:30PM	Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis (GlobeNewswire)
Mar-19-26 04:05PM	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-18-26 08:00AM	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
08:05AM	Loading…
Mar-02-26 08:05AM	Alumis to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-26 08:10PM	Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference (MarketBeat)
Feb-12-26 11:42AM	Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit (MarketBeat)
Feb-05-26 08:05AM	Alumis to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 09:48AM	Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials (Insider Monkey) -8.68%
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com) +9.22%
Jan-15-26 04:12PM	David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 (Benzinga)
11:35AM	HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating (Insider Monkey)
Jan-09-26 04:05PM	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.59% +7.82%
Jan-08-26 08:56AM	What's Going On With Alumis Stock Thursday? (Benzinga)
Jan-07-26 10:52PM	Alumis Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +10.41%
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:35AM	Should You Chase the Rally in Alumis Stock Today? (Barchart)
Jan-06-26 05:30PM	Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover (Investor's Business Daily) +95.31%
04:29PM	Loading…
04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
04:12PM	Alumis Announces Proposed Public Offering of Common Stock (GlobeNewswire)
10:59AM	Alumis Stock Hits Record High on Psoriasis Drug Trial Results (Schaeffer's Research)
07:00AM	Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program (GlobeNewswire)
Jan-05-26 05:00PM	Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire) -7.20%
Nov-13-25 04:15PM	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-04-25 08:00AM	Alumis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Aug-29-25 07:00AM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 05:31PM	TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications \| DelveInsight (PR Newswire)
Jul-29-25 10:23AM	Alumis (ALMS) Merges with ACELYRIN (Insider Monkey)
Jul-24-25 07:30AM	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Jul-14-25 04:05PM	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary (GlobeNewswire)
May-30-25 05:23AM	Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy (Clinical Trials Arena) -10.49%
May-29-25 04:15PM	Alumis to Present at the Jefferies Global Healthcare Investor Conference (GlobeNewswire)
07:55AM	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
May-21-25 09:10AM	Alumis Completes Merger with ACELYRIN (GlobeNewswire)
May-14-25 04:05PM	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire) +18.63%
May-13-25 01:00PM	Alumis Stockholders Approve Merger with ACELYRIN (GlobeNewswire) -15.05%
01:00PM	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire)
May-06-25 04:30PM	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote FOR the Proposed Transaction with Alumis (GlobeNewswire) +10.11%
May-02-25 01:45PM	Acelyrin urges stockholders to vote for proposed merger with Alumis (TipRanks) +19.84%
May-01-25 01:30PM	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis (GlobeNewswire) -7.49%
Apr-29-25 01:22PM	Acelyrin should liquidate instead of merging with Alumis, investor says (BioPharma Dive) +5.10%
Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -6.00%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Sep 08 '26	Buy	10.63	546,581	5,808,571	4,937,026	Sep 09 09:39 PM
AKKARAJU SRINIVAS	Director	Sep 04 '26	Buy	11.17	440,140	4,917,684	4,711,801	Sep 09 09:39 PM
AKKARAJU SRINIVAS	Director	Sep 08 '26	Sale	10.55	96,131	1,014,028	2,025,493	Sep 09 09:39 PM
Schroer John R.	Chief Financial Officer	Aug 03 '26	Sale	26.37	3,282	86,546	24,718	Aug 05 06:50 PM
Pangali Sanam	Chief Legal Officer	Aug 03 '26	Sale	26.37	1,364	35,969	9,747	Aug 05 06:46 PM
Hardiman Roy C.	Chief Business & Strategy Ofcr	Aug 03 '26	Sale	26.37	2,692	70,988	207,746	Aug 05 06:44 PM
Goldstein David M	Chief Scientific Officer	Aug 03 '26	Sale	26.37	2,596	68,457	30,970	Aug 05 06:40 PM
Drappa Jorn	Chief Medical Officer	Aug 03 '26	Sale	26.37	2,447	64,527	56,892	Aug 05 06:36 PM
Bradley Mark Christopher	Chief Development Officer	Aug 03 '26	Sale	26.37	2,572	67,824	48,533	Aug 05 06:21 PM
Pangali Sanam	Chief Legal Officer	Jul 06 '26	Option Exercise	5.06	5,000	25,300	16,111	Jul 08 04:40 PM
Pangali Sanam	Chief Legal Officer	Jul 06 '26	Sale	28.00	5,000	140,000	11,111	Jul 08 04:40 PM
SANAMPREET PANGALI	Officer	Jul 06 '26	Proposed Sale	28.00	5,000	140,000		Jul 06 04:06 PM
Drappa Jorn	Chief Medical Officer	May 22 '26	Option Exercise	6.65	26,852	178,649	59,339	May 27 07:06 PM
AKKARAJU SRINIVAS	Director	Jan 09 '26	Buy	17.00	588,235	9,999,995	1,853,488	Jan 13 06:20 PM
Foresite Labs, LLC	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:59 PM
Foresite Capital Management VI	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
Tananbaum James B.	Director	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
AKKARAJU SRINIVAS	Director	Dec 05 '25	Buy	9.84	186,377	1,833,760	1,265,253	Dec 09 07:13 PM
AKKARAJU SRINIVAS	Director	Dec 03 '25	Buy	7.75	100,000	775,000	1,012,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 02 '25	Buy	7.55	96,000	724,800	912,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 04 '25	Buy	8.18	66,027	540,101	1,078,876	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 01 '25	Buy	7.46	86,350	644,171	816,849	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 26 '25	Buy	7.64	48,537	370,823	691,797	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 28 '25	Buy	7.64	38,702	295,683	730,499	Dec 01 06:09 PM
Foresite Capital Management VI	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Tananbaum James B.	Director	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Foresite Labs, LLC	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:01 PM
AKKARAJU SRINIVAS	Director	Nov 20 '25	Buy	7.20	125,743	905,350	643,260	Nov 24 06:50 PM
Foresite Labs, LLC	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:54 PM
Foresite Capital Management VI	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:52 PM
Tananbaum James B.	Director	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:51 PM
AKKARAJU SRINIVAS	Director	Nov 19 '25	Buy	6.56	137,772	903,784	517,517	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 18 '25	Buy	6.05	102,652	621,045	379,745	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 17 '25	Buy	5.51	914	5,036	277,093	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 13 '25	Buy	5.25	276,179	1,449,940	276,179	Nov 17 04:59 PM

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

PresidentMr. Martin Babler Ph.D.

Chief Scientific OfficerDr. David M. Goldstein Ph.D.

Ph.D.Dr. Jorn Drappa M.D.

Chief Financial OfficerMr. John R. Schroer C.F.A.

Chief Legal Officer & Corporate SecretaryMs. Sanam Pangali J.D.

Open in Screener

KLRS

Kalaris Therapeutics Inc

1.86

Oct 27 • 3:59 PM ET +0.06 (3.33%)

1.89

Aftermarket • 7:30 PM ET +0.03 (1.61%)

Healthcare Biotechnology USA Nano NASD

KLRS Kalaris Therapeutics Inc daily Stock Chart

Peers: OTLK KOD EYPT OCUL FDMT RGNX REGN IRD OCGN OKYO

| Held by: VTI VXF IWC BUSM DCOR DXUV DFAC

Index	-
Market Cap	40.62M
Enterprise Value	-51.52M
Income	-44.26M
Sales	0.00M
Book/sh	2.42
Cash/sh	4.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	20
IPO	Jul 30, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.77
P/C	0.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.92
Current Ratio	10.92
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-2.01
EPS next Y	-1.65
EPS next Q	-0.52
EPS this Y	29.78%
EPS next Y	17.43%
EPS next 5Y	5.48%
EPS past 3/5Y	61.69% 45.59%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.44%
Sales Y/Y TTM	-
EPS Q/Q	20.27%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	3.03% -

Insider Own	63.69%
Insider Trans	1.79%
Inst Own	19.77%
Inst Trans	-2.22%
ROA	-46.02%
ROE	-79.91%
ROIC	-75.37%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-18.56%
SMA50	-39.42%
SMA200	-66.25%
Trades

Shs Outstand	23.80M
Shs Float	8.64M
Short Float	3.55%
Short Ratio	4.28
Short Interest	0.31M
52W High	11.88 -84.34%
52W Low	1.78 4.49%
Volatility	7.00% 8.21%
ATR (14)	0.18
RSI (14)	25.10
Beta	0.44
Rel Volume	0.71
Avg Volume	71.63K
Volume	51,130

Perf Week	-10.14%
Perf Month	-34.62%
Perf Quarter	-45.29%
Perf Half Y	-66.99%
Perf YTD	-77.96%
Perf Year	-61.73%
Perf 3Y	-93.96%
Perf 5Y	-99.67%
Perf 10Y	-
Recom	1.25
Target Price	18.71
Prev Close	1.80
Price	1.86
Change %	3.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-26	Initiated	TD Cowen	Buy
May-14-26	Initiated	Wedbush	Outperform	$17
Apr-16-26	Initiated	Morgan Stanley	Overweight	$14
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$19
Nov-03-25	Initiated	Citizens JMP	Mkt Outperform	$20
Sep-03-25	Initiated	Raymond James	Strong Buy	$23
Jul-23-25	Resumed	Piper Sandler	Neutral	$3
May-07-25	Initiated	Leerink Partners	Outperform	$20
Apr-08-25	Initiated	William Blair	Outperform

Aug-31-26 08:00AM	Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-26 08:00AM	Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-20-26 08:00AM	Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer (GlobeNewswire) -8.68%
Jul-17-26 07:00AM	Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts (GlobeNewswire)
Jul-06-26 04:05PM	Kalaris Appoints Laurie Keating to Board of Directors (GlobeNewswire)
08:00AM	Loading…
Jun-23-26 08:00AM	Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling (GlobeNewswire)
Jun-12-26 08:00AM	Kalaris to Present at Clinical Trials at the Summit 2026 (GlobeNewswire)
May-14-26 09:45AM	Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly) +8.07%
May-12-26 08:00AM	Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jan-28-26 04:05PM	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting (GlobeNewswire)
Dec-17-25 05:59PM	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement (GlobeNewswire) +20.32%
04:01PM	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD (GlobeNewswire)
Nov-24-25 08:00AM	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (Newsfile) -7.99%
Nov-12-25 08:00AM	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 07:30AM	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer (GlobeNewswire)
08:00AM	Loading…
Oct-30-25 08:00AM	Kalaris to Present at Stifel 2025 Annual Healthcare Conference (GlobeNewswire)
Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	May 20 '26	Buy	4.83	244,300	1,179,969	2,224,147	May 22 07:47 PM
Hagen Brett R	Chief Accounting Officer	Mar 20 '26	Sale	6.72	1,915	12,869	0	Mar 23 04:05 PM
BRETT R R HAGEN	Officer	Mar 20 '26	Proposed Sale	6.72	1,915	12,869		Mar 20 04:07 PM
AKKARAJU SRINIVAS	Director	Dec 18 '25	Buy	10.42	479,847	5,000,006	1,979,847	Feb 17 08:15 PM

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.

PresidentMr. Andrew Oxtoby

Ph.D.Dr. Srinivas Akkaraju M.D.

Co-Founder & DirectorDr. Michael Philip Dybbs Ph.D.

Independent Director & Co-FounderDr. Napoleone Ferrara M.D.

Chief Medical OfficerDr. Matthew Feinsod M.D.

Open in Screener

MLYS

Mineralys Therapeutics Inc

21.13

Oct 27 • 3:59 PM ET +0.57 (2.77%)

21.13

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

MLYS Mineralys Therapeutics Inc daily Stock Chart

Peers: NAMS ALNY AZN MAZE VERA ARDX CYTK ARWR MIST AKBA

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA DFAS VHT

Index	RUT
Market Cap	1.87B
Enterprise Value	1.30B
Income	-349.58M
Sales	0.00M
Book/sh	6.24
Cash/sh	7.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Feb 10, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.39
P/C	2.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	34.46
Current Ratio	34.46
Debt/Eq	0.18
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	-4.24
EPS next Y	-2.39
EPS next Q	-0.55
EPS this Y	-95.79%
EPS next Y	46.63%
EPS next 5Y	18.42%
EPS past 3/5Y	-46.34% -101.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	-19.00%
Sales Y/Y TTM	-
EPS Q/Q	-330.32%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-419.50% -

Insider Own	31.19%
Insider Trans	-1.67%
Inst Own	89.15%
Inst Trans	12.14%
ROA	-69.67%
ROE	-80.88%
ROIC	-53.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.69%
SMA50	-15.97%
SMA200	-22.27%
Trades

Shs Outstand	88.35M
Shs Float	60.84M
Short Float	12.23%
Short Ratio	6.54
Short Interest	7.44M
52W High	47.65 -55.66%
52W Low	20.12 5.02%
Volatility	4.49% 5.59%
ATR (14)	1.23
RSI (14)	40.38
Beta	0.74
Rel Volume	2.81
Avg Volume	1.14M
Volume	3,199,949

Perf Week	-2.09%
Perf Month	-17.56%
Perf Quarter	-19.81%
Perf Half Y	-18.39%
Perf YTD	-41.77%
Perf Year	-47.90%
Perf 3Y	178.03%
Perf 5Y	-
Perf 10Y	-
Recom	1.40
Target Price	46.33
Prev Close	20.56
Price	21.13
Change %	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Initiated	UBS	Neutral	$29
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold	$15
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Show Previous Ratings

Oct-22-26 06:40PM	Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 (GlobeNewswire)
Oct-19-26 04:05PM	Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats (GlobeNewswire)
Oct-09-26 09:00AM	Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire)
Oct-02-26 04:30PM	Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 (GlobeNewswire)
Oct-01-26 04:05PM	Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire) -5.61%
04:05PM	Loading…
Sep-29-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-26 04:05PM	Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-23-26 04:05PM	Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 (GlobeNewswire) -8.54%
Sep-21-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-26 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-13-26 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 01:01AM	Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-26 04:05PM	Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-26 08:00AM	Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 (GlobeNewswire)
04:01PM	Loading…
Jul-27-26 04:01PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-26 10:00AM	Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-08-26 04:05PM	Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -5.02% +7.47%
07:00AM	Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-03-26 06:05AM	Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) -13.14%
06:00AM	Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing (GlobeNewswire)
May-30-26 11:15AM	Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-27-26 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-18-26 04:05PM	Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-06-26 04:05PM	Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-26 05:34PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-26 04:05PM	Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +15.23%
Mar-24-26 08:00AM	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer (GlobeNewswire)
04:05PM	Loading…
Mar-16-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 11:06PM	Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 04:30PM	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 (GlobeNewswire)
Feb-26-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 07:00PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Jan-30-26 12:24AM	Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones (Insider Monkey)
Jan-06-26 08:00AM	Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rodman David Malcom	Officer	Oct 13 '26	Proposed Sale	22.04	3,542	78,066		Oct 13 04:11 PM
Congleton Jon	Chief Executive Officer	Sep 30 '26	Sale	25.46	75,000	1,909,665	528,621	Oct 02 05:53 PM
Congleton Jon	Officer	Sep 30 '26	Proposed Sale	25.46	75,000	1,909,662		Sep 30 04:07 PM
Slingsby Brian Taylor	Director	Sep 22 '26	Sale	28.81	104,320	3,005,303	7,805,718	Sep 24 09:49 PM
Warren Eric	Chief Commercial Officer	Sep 21 '26	Option Exercise	13.24	7,438	98,479	45,838	Sep 22 06:48 PM
Warren Eric	Chief Commercial Officer	Sep 21 '26	Sale	28.12	7,438	209,136	38,400	Sep 22 06:48 PM
CATALYS PACIFIC FUND LP	Director	Sep 22 '26	Proposed Sale	28.81	104,320	3,005,303		Sep 22 04:09 PM
Warren Eric	Officer	Sep 21 '26	Proposed Sale	28.12	7,438	209,135		Sep 21 04:05 PM
Karydas Daphne	Director	Sep 15 '26	Option Exercise	12.02	3,000	36,060	9,200	Sep 17 05:41 PM
Karydas Daphne	Director	Sep 15 '26	Sale	28.58	3,000	85,740	6,200	Sep 17 05:41 PM
Rodman David Malcom	Officer	Sep 17 '26	Proposed Sale	27.95	417	11,655		Sep 17 04:06 PM
Karydas Daphne	Officer	Sep 15 '26	Proposed Sale	28.58	3,000	85,740		Sep 15 04:19 PM
Rodman David Malcom	Officer	Sep 14 '26	Proposed Sale	28.14	7,709	216,931		Sep 14 04:06 PM
Rodman David Malcom	Officer	Sep 09 '26	Proposed Sale	30.87	2,171	67,019		Sep 09 04:05 PM
Warren Eric	Chief Commercial Officer	Aug 21 '26	Option Exercise	13.24	7,437	98,466	45,837	Aug 25 05:16 PM
Warren Eric	Chief Commercial Officer	Aug 21 '26	Sale	25.98	7,437	193,189	38,400	Aug 25 05:16 PM
Warren Eric	Officer	Aug 21 '26	Proposed Sale	25.98	7,437	193,188		Aug 21 04:14 PM
Rodman David Malcom	Officer	Aug 17 '26	Proposed Sale	25.46	417	10,617		Aug 17 04:38 PM
Rodman David Malcom	Officer	Aug 13 '26	Proposed Sale	26.48	14,056	372,187		Aug 13 04:12 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '26	Option Exercise	16.00	2,170	34,720	53,554	Aug 12 07:33 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '26	Sale	27.09	2,170	58,785	51,384	Aug 12 07:33 PM
Rodman David Malcom	Officer	Aug 10 '26	Proposed Sale	27.09	2,170	58,785		Aug 10 04:39 PM
Warren Eric	Chief Commercial Officer	Jul 21 '26	Option Exercise	13.24	7,438	98,479	45,838	Jul 23 06:39 PM
Warren Eric	Chief Commercial Officer	Jul 21 '26	Sale	26.87	7,438	199,885	38,400	Jul 23 06:39 PM
Warren Eric	Officer	Jul 21 '26	Proposed Sale	26.87	7,438	199,885		Jul 21 04:11 PM
Rodman David Malcom	Chief Medical Officer	Jul 17 '26	Option Exercise	15.44	416	6,423	51,800	Jul 20 09:00 PM
Rodman David Malcom	Chief Medical Officer	Jul 17 '26	Sale	26.53	416	11,036	51,384	Jul 20 09:00 PM
Rodman David Malcom	Officer	Jul 17 '26	Proposed Sale	26.48	416	11,016		Jul 17 04:03 PM
Congleton Jon	Chief Executive Officer	Jul 13 '26	Sale	27.24	10,700	291,441	603,621	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 13 '26	Option Exercise	7.28	14,058	102,365	71,791	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 13 '26	Sale	27.58	14,058	387,717	57,733	Jul 15 08:58 PM
Rodman David Malcom	Chief Medical Officer	Jul 15 '26	Sale	26.61	6,349	168,955	51,384	Jul 15 08:58 PM
Rodman David Malcom	Officer	Jul 15 '26	Proposed Sale	26.61	6,349	168,955		Jul 15 04:13 PM
Congleton Jon	Officer	Jul 13 '26	Proposed Sale	27.24	10,700	291,441		Jul 13 04:23 PM
Rodman David Malcom	Officer	Jul 13 '26	Proposed Sale	26.72	14,508	387,717		Jul 13 04:22 PM
Rodman David Malcom	Chief Medical Officer	Jul 09 '26	Option Exercise	16.00	2,171	34,736	59,904	Jul 10 07:15 PM
Rodman David Malcom	Chief Medical Officer	Jul 09 '26	Sale	30.30	2,171	65,781	57,733	Jul 10 07:15 PM
Rodman David Malcom	Officer	Jul 09 '26	Proposed Sale	30.30	2,171	65,781		Jul 09 04:10 PM
Congleton Jon	Chief Executive Officer	Jun 30 '26	Sale	26.14	75,000	1,960,601	614,321	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Option Exercise	13.24	104,124	1,378,602	142,524	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Sale	25.90	104,124	2,696,322	38,400	Jun 30 06:41 PM
Congleton Jon	Officer	Jun 30 '26	Proposed Sale	26.14	75,000	1,960,602		Jun 30 04:20 PM
Warren Eric	Officer	Jun 26 '26	Proposed Sale	25.90	104,124	2,696,322		Jun 29 09:05 AM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Option Exercise	14.36	4,584	65,818	61,679	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Option Exercise	10.20	3,542	36,128	66,985	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Sale	23.81	9,890	235,487	57,095	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Sale	25.00	4,584	114,600	57,095	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Option Exercise	12.02	3,000	36,060	9,200	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Sale	25.00	3,000	75,000	6,200	Jun 17 09:18 PM
Rodman David Malcom	Officer	Jun 17 '26	Proposed Sale	25.00	4,584	114,600		Jun 17 04:20 PM
Karydas Daphne	Officer	Jun 17 '26	Proposed Sale	25.00	3,000	75,000		Jun 17 04:15 PM
Rodman David Malcom	Officer	Jun 15 '26	Proposed Sale	23.81	9,890	235,487		Jun 15 04:58 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Option Exercise	16.00	2,170	34,720	65,613	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Option Exercise	1.08	6,349	6,857	69,792	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Sale	23.93	6,349	151,901	63,443	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Sale	25.00	2,170	54,250	63,443	Jun 12 06:04 PM
Rodman David Malcom	Officer	Jun 12 '26	Proposed Sale	23.93	6,349	151,901		Jun 12 04:17 PM
Rodman David Malcom	Officer	Jun 10 '26	Proposed Sale	25.00	2,170	54,250		Jun 10 04:11 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Option Exercise	15.44	417	6,438	63,860	May 19 07:15 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Sale	27.55	417	11,488	63,443	May 19 07:15 PM
Rodman David Malcom	Officer	May 18 '26	Proposed Sale	27.55	417	11,488		May 18 04:10 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Option Exercise	12.39	7,707	95,484	77,499	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Option Exercise	16.00	2,171	34,736	71,963	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Option Exercise	1.08	6,348	6,856	76,140	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Sale	28.58	14,056	401,789	63,443	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Sale	29.36	6,348	186,348	69,792	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Sale	29.71	2,171	64,500	69,792	May 13 09:42 PM
Rodman David Malcom	Officer	May 13 '26	Proposed Sale	28.58	14,056	401,790		May 13 04:11 PM
Rodman David Malcom	Officer	May 12 '26	Proposed Sale	29.36	6,348	186,348		May 12 05:05 PM
Rodman David Malcom	Officer	May 11 '26	Proposed Sale	29.71	2,171	64,500		May 11 04:27 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Option Exercise	15.44	416	6,423	70,208	Apr 21 06:59 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Sale	31.33	416	13,033	69,792	Apr 21 06:59 PM
Rodman David Malcom	Officer	Apr 17 '26	Proposed Sale	31.33	416	13,033		Apr 17 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Option Exercise	7.28	14,058	102,365	90,198	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Sale	26.54	14,058	373,087	76,140	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 15 '26	Sale	27.66	6,348	175,586	69,792	Apr 15 09:45 PM
Congleton Jon	Chief Executive Officer	Apr 13 '26	Sale	26.83	15,730	421,979	689,321	Apr 15 09:45 PM
Rodman David Malcom	Officer	Apr 15 '26	Proposed Sale	27.66	6,348	175,586		Apr 15 04:21 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Option Exercise	16.00	2,170	34,720	78,310	Apr 13 09:13 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Sale	27.38	2,170	59,415	76,140	Apr 13 09:13 PM
Congleton Jon	Officer	Apr 13 '26	Proposed Sale	26.83	15,730	421,980		Apr 13 04:22 PM
Rodman David Malcom	Officer	Apr 13 '26	Proposed Sale	26.54	14,058	373,087		Apr 13 04:18 PM
Rodman David Malcom	Officer	Apr 09 '26	Proposed Sale	27.38	2,170	59,415		Apr 09 04:24 PM
Congleton Jon	Chief Executive Officer	Mar 31 '26	Sale	26.27	75,000	1,970,522	705,051	Apr 02 06:54 PM
Karydas Daphne	Director	Mar 31 '26	Option Exercise	12.02	3,000	36,060	9,200	Apr 02 06:53 PM
Karydas Daphne	Director	Mar 31 '26	Sale	25.00	3,000	75,000	6,200	Apr 02 06:53 PM
Karydas Daphne	Officer	Mar 31 '26	Proposed Sale	25.00	3,000	75,000		Mar 31 04:18 PM
Congleton Jon	Officer	Mar 31 '26	Proposed Sale	26.27	75,000	1,970,521		Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '26	Buy	23.67	310,700	7,354,269	5,767,221	Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 30 '26	Buy	24.16	58,300	1,408,528	5,825,521	Mar 31 04:15 PM
Rodman David Malcom	Officer	Mar 17 '26	Proposed Sale	25.65	417	10,696		Mar 17 05:04 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Option Exercise	15.44	417	6,438	76,557	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Sale	25.65	417	10,696	76,140	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Option Exercise	12.39	7,709	95,508	90,198	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Option Exercise	1.08	6,348	6,856	88,837	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Sale	26.26	14,058	369,225	76,140	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Sale	27.37	6,348	173,748	82,489	Mar 16 05:20 PM
Rodman David Malcom	Officer	Mar 13 '26	Proposed Sale	26.26	14,058	369,225		Mar 13 04:50 PM
Rodman David Malcom	Officer	Mar 12 '26	Proposed Sale	27.37	6,348	173,748		Mar 12 04:13 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Option Exercise	16.00	2,171	34,736	84,660	Mar 10 05:48 PM

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

PresidentDr. Jon Congleton

M.P.H.Dr. Brian Taylor Slingsby M.D.

CFO & SecretaryMr. Adam Scott Levy

Chief Legal OfficerMr. Jeffrey A. Munsie J.D.

Senior Vice President of CMCDr. Robert McKean Ph.D.

SRRK

Scholar Rock Holding Corp

ALMS

Alumis Inc

KLRS

Kalaris Therapeutics Inc

MLYS

Mineralys Therapeutics Inc

Upgrade your Finviz experience